ORCID as entered in ROS
https://orcid.org/0000-0002-4741-2622
Select Publications
Journal articles
, 1998, 'Epidemiological and social research findings reported at the 12th World AIDS Conference, Geneva 1998', Australian HIV Surveillance Report, 14, pp. 1 - 9
, 1998, 'Estimates and projections of the hepatitis C virus epidemic in Australia', ION Meeting Proceedings
, 1998, 'HIV and AIDS in the Asia-Pacific region: an epidemiological overview', AIDS, 12, pp. S1 - S10
, 1998, 'Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study', British Medical Journal: International, pp. 433 - 437
, 1998, 'Kaposi¿s sarcoma and protection from AIDS dementia complex', AIDS, 12, pp. 2354 - 2355
, 1998, 'Polymerase chain reaction as marker of infectivity in people with hepatitis C', British Medical Journal: International, pp. 553 - 554
, 1998, 'Report from the 4th International Conference on AIDS in Asia and the Pacific', Noah's Arc
, 1998, 'Sexually transmissible diseases surveillance in Australia: towards a coordinated national system', Annual report of the Australian Meningococcal Surveillance Programme, 2007--Amended, pp. 49 - 52
, 1998, 'Trends in infectious disease mortality in Australia, 1979-1994', Medical Journal of Australia, 168, pp. 601 - 604
, 1998, 'Trends in infectious disease mortality rates', Medical Journal of Australia, 169, pp. 444 - 445
, 1997, 'Isoniazid prophylaxis for high-risk patients with anergy and HIV infection [4] (multiple letters)', New England Journal of Medicine, 337, pp. 1696 - 1697, http://dx.doi.org/10.1056/NEJM199712043372316
, 1997, 'Isoniazid prophylaxis for high-risk patients with anergy and HIV infection.', The New England journal of medicine, 337, pp. 1697
, 1997, 'Prospective analysis of seizures occurring in human immunodeficiency virus type-1 infection', Journal of Neuro-AIDS, 1, pp. 59 - 69, http://dx.doi.org/10.1300/J128v01n04_06
, 1997, '"HIV-1 Infection among Female Commercial Sex Workers in Rural Thailand."', Studies in Family Planning, 28, pp. 168 - 168, http://dx.doi.org/10.2307/2138125
, 1997, 'A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis', New England Journal of Medicine, pp. 315 - 320
, 1997, 'HIV-1 infection among female commercial sex workers in rural Thailand', AIDS, 11, pp. 89 - 94
, 1997, 'Systematic review of role of polymerase chain reaction in defining infectiousness among people with hepatitis C virus', British Medical Journal: Clinical Research, pp. 333 - 337
, 1997, 'Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS Cohort', Journal of acquired immune deficiency syndrome and human retrovirology, 16, pp. 39 - 43
, 1996, 'Epidemiology of HIV and AIDS in the Asia-Pacific region', Medical Journal of Australia, 165, pp. 494 - 498, http://dx.doi.org/10.5694/j.1326-5377.1996.tb138615.x
, 1996, 'Managing HIV .9. HIV in Asia and the Pacific - Epidemiology of HIV and AIDS in the Asia-Pacific region', MEDICAL JOURNAL OF AUSTRALIA, 165, pp. 494 - 498, http://dx.doi.org/10.5694/j.1326-5377.1996.tb138615.x
, 1996, 'Declining incidence and later occurrence of Kaposi`s sarcoma among people with AIDS in Australia: the Australian AIDS cohort', AIDS, 10, pp. 1401 - 1406
, 1996, 'Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room', AIDS, 10, pp. 521 - 525
, 1996, 'The use of back-projection to estimate HIV prevalence in pregnant women', Paediatric AIDS and HIV Infection, pp. 331 - 336
, 1995, 'Clinico-pathological study of cytomegalovirus infection (CMV) is AIDS autopsies: under-recognition of CMV pneumonitis and CMV adrenalitis', Australian and New Zealand Journal of Medicine, pp. 503 - 506
, 1995, 'Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with Human Immunodeficiency virus: Response to therapy with Albendazole', Clinical Infectious Diseases, pp. 70 - 76
Conference Papers
, 2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study', in International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2022.103706
, 2021, '"WE'VE HAD A CIRCUIT BREAKER FOR AN OLD DOGMA OF MORE THAN 20 YEARS": CHANGES TO OPIOID AGONIST TREATMENT SERVICES DURING COVID-19, THE CHOICE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S59 - S59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200148&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2021, 'OPIOID OVERDOSE AND NALOXONE ACCESS AMONG PEOPLE WHO RECENTLY USED OPIOIDS OR RECEIVED OPIOID AGONIST TREATMENT IN AUSTRALIA: THE ETHOS ENGAGE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S59 - S60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200149&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'RESTORATION OF HCV-SPECIFIC T CELLS FOLLOWING DAA THERAPY IN ACUTE HCV INFECTION-SUPPORT FOR TREATMENT OF ACUTE INFECTION.', in HEPATOLOGY, WILEY, ELECTR NETWORK, pp. 613A - 614A, presented at
, 2020, 'Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis', in JOURNAL OF HEPATOLOGY, ELSEVIER, pp. S363 - S363, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587001118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'BARRIERS AND FACILITATORS TO ENGAGING IN HEPATITIS C MANAGEMENT AND DIRECT-ACTING ANTIVIRAL THERAPY AMONG GENERAL PRACTITIONERS AND DRUG AND ALCOHOL SPECIALISTS: THE PRACTITIONER EXPERIENCE', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S9 - S9, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Efficacy and safety of sofosbuvir, velpatasvir, and voxilaprevir in NS5A-experienced patients with advanced liver disease or prior liver transplantation: The first Australian real-world experience', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 72 - 73, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2018, 'Drug and alcohol use patterns during and following treatment with sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use: Insights from trajectory analyses', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, pp. 31 - 32, presented at
, 2018, 'Evaluation of a hepatitis C virus core antigen assay in dried-blood spots: a cohort study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S317 - S318, presented at
, 2018, 'Evaluation of the Xpert fingerstick HCV viral load assay', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S167 - S167, presented at
, 2018, 'Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S187 - S188, presented at
, 2017, 'A RANDOMISED CLINICAL TRIAL OF BACLOFEN FOR THE TREATMENT OF ALCOHOL DEPENDENCE', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 53 - 53, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500138&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR-BASED DIRECT-ACTING ANTIVIRAL THERAPIES FOR HEPATITIS C VIRUS INFECTION IN PATIENTS RECEIVING OPIOID SUBSTITUTION THERAPY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 34 - 35, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500086&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2017, 'Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B', in HEPATOLOGY, WILEY, DC, Washington, pp. 112A - 113A, presented at
, 2017, 'Field evaluation of Xpert (R) HCV Viral Load point-of-care test for detection of hepatitis C virus infection by venipuncture-collected and finger-stick capillary whole-blood samples', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S709 - S709, presented at
, 2017, 'Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S274 - S274, presented at
, 2017, 'Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S488 - S488, presented at
, 2017, 'Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S514 - S514, presented at
, 2017, 'Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir plus /- ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis -Final results of the REV1TAL study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S521 - S521, presented at
, 2016, 'A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study', in HEPATOLOGY, WILEY, MA, Boston, pp. 135A - 136A, presented at
, 2016, 'Excellent SVR12 rates with Viekira Pak in a real-world cohort of HCV Genotype 1 patients predominantly with cirrhosis - the Australian REV1TAL Study', in HEPATOLOGY, WILEY, MA, Boston, pp. 483A - 484A, presented at
, 2016, 'Frequency and severity of biochemical abnormalities with paritaprevir/ritonavir/ombitasvir +/- ribavirin in a real-world cohort of HCV Genotype 1 patients - predictors and clinical significance', in HEPATOLOGY, WILEY, MA, Boston, pp. 442A - 442A, presented at
, 2016, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with recent Hepatitis C virus infection, including for post-treatment relapse', in HEPATOLOGY, WILEY, MA, Boston, pp. 415A - 415A, presented at
, 2016, 'Hepatitis C virus exposure, infection and associated risk behaviours in two maximum-security prisons in New South Wales, Australia', in HEPATOLOGY, WILEY, MA, Boston, pp. 385A - 386A, presented at
, 2016, 'C-EDGE CO-STAR: Risk of reinfection following successful therapy with elbasvir and grazoprevir in persons who inject drugs (PWID) receiving opioid agonist therapy (OAT)', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 70 - 71, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000384664700128&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Filter by type
https://orcid.org/0000-0002-4741-2622